Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, Open Label, Dose-escalation Study of the Combination of BI 907828 (Brigimadlin) With BI 754091 (Ezabenlimab) and BI 754111 and the Combination of BI 907828 (Brigimadlin) With BI 754091(Ezabenlimab) Followed by Expansion Cohorts, in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase Ia/Ib, Open Label, Dose-escalation Study of the Combination of BI 907828 (Brigimadlin) With BI 754091 (Ezabenlimab) and BI 754111 and the Combination of BI 907828 (Brigimadlin) With BI 754091(Ezabenlimab) Followed by Expansion Cohorts, in Patients With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brigimadlin (Primary) ; Ezabenlimab (Primary) ; Miptenalimab (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Gastric cancer; Liposarcoma; Liver cancer; Malignant fibrous histiocytoma; Malignant melanoma; Non-small cell lung cancer; Periampullary cancer; Sarcoma; Skin cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 13 May 2024 Status changed from recruiting to active, no longer recruiting.
  • 20 Jan 2024 Results of pooled analysis from NCT03449381 and NCT03964233, for safety and efficacy, presented at the 2024 Gastrointestinal Cancers Symposium
  • 21 Jan 2023 Results from two phase Ia/Ib dose-escalation/expansion trials(n=8, NCT03449381 and NCT03964233) assessing Efficacy and safety of BI 907828 in patients with advanced biliary tract cancer presented at the 2023 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top